SP Research, PLLC

Oklahoma City, Oklahoma 73112

1 studies enrolling now · 14 studies all time

What they study most

ADHD, ADHD - Combined Type, Acute Mania, Attention Deficit Hyper Activity, Attention Deficit Hyperactivity Disorder, Attention Deficit Hyperactivity Disorder Combined, Attention Deficit/Hyperactivity Disorder, Attention-Deficit/Hyperactivity Disorder (ADHD), Attention-deficit Hyperactivity, Bipolar I Disorder, Chronic Lower Back Pain, Chronic Pain

Studies at this site

• A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder — Recruiting now
• A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder. — Completed
• A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study — Stopped early
• Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users — Completed
• Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301 — Completed
• An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5) — Completed
• Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD — Completed
• Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain — Completed
• Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder — Completed
• A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder. — Completed
• A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder — Completed
• Open-Label Treatment Extension Study — Completed
• A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) — Completed
• Switching to Iloperidone From Other Antipsychotics in Schizophrenia — Completed